Novartis

February 4, 2019
Categories

Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment

[vc_row][vc_column][vc_column_text] Cell and gene therapies (CGTs) offer an unprecedented opportunity to treat diseases for which existing interventions are inadequate, potentially offering cures for previously terminal illnesses. […]
Do you like it?
Read more
August 31, 2017
The CAR-T Revolution: Gilead’s $12B Acquisition of Kite Pharma & FDA Approval of Novartis’ Kymriah Signal Tipping Point for Promising Cancer Immunotherapies
Categories

The CAR-T Revolution: Gilead’s $12B Acquisition of Kite Pharma & FDA Approval of Novartis’ Kymriah Signal Tipping Point for Promising Cancer Immunotherapies

[vc_row][vc_column][vc_column_text] Gilead Sciences has ended its M&A moratorium with an $11.9B all-cash acquisition of CAR-T Cell Therapy pioneers Kite Pharma. Kite’s leading drug Axi-Cel is expected […]
Do you like it?
Read more
November 29, 2016
Categories

Promising Autologous CAR-T Cell Therapies Stumble: is this the End, or Just the Beginning?

[vc_row][vc_column][vc_column_text]The field of CAR-T immunotherapy presents a tantalising idea: reengineering a patient’s immune cells to attack cancer. CAR-T immunotherapy has the potential to revolutionise the way […]
Do you like it?
Read more